Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Omeros Corporation(OMER)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for OMER
10/19/2026: OMER (5-star) is a SELL. SELL for 2 days. Simulated Profits (36.82%). Updated daily EoD!
Omeros Corporation is a clinical-stage biotechnology company focused on developing therapies for rare diseases and inflammatory conditions. Its primary business strengths lie in its proprietary MASP-2 and GPCR technology platforms, which support a niche pipeline. The main investment story centers on the potential regulatory approval of narsoplimab, which could provide significant upside. However, investors face high risks including binary regulatory outcomes, the lack of current commercial revenue, and intense competition from well-funded rivals. The stock may suit growth-oriented investors with a high risk tolerance who are looking for speculative exposure to drug development, and investors should closely monitor upcoming FDA communications and clinical data releases.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high growth potential linked to pipeline success but carries extreme clinical development risks. |
| Momentum investor | Strong fit while signal remains positive | The stock can exhibit high volatility and strong price swings around clinical news, attracting momentum-based interest. |
| Value investor | Weak fit | Omeros currently lacks the earnings and fundamental cash flow stability typically required for value investing. |
| Dividend investor | Weak fit | The company does not pay dividends and focuses entirely on reinvestment. |
| Low-risk investor | Weak fit | The binary nature of clinical development creates high risk and significant price volatility unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotech stocks often experience sharp price changes based on regulatory or clinical data releases. |
| Valuation risk | High | Valuations are highly speculative as they depend on the potential future success of pipeline drugs. |
| Competition risk (Complement inhibition market) | High | Omeros faces stiff competition from established players with deeper resources and approved products. |
| Business quality | Medium | The company relies on its proprietary platforms, but the lack of commercialized revenue streams limits the current quality profile. |
| Dividend income | Low / none | Investors should expect zero income from this equity. |
| Execution risk | High | Success depends on managing complex clinical trials and achieving positive regulatory outcomes. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type Stock | Historic Profit 154.66% | Avg. Invested days 26 | Today’s Advisory SELL |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/19/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.17B USD | Price to earnings Ratio 13.28 | 1Y Target Price 27.5 |
Price to earnings Ratio 13.28 | 1Y Target Price 27.5 | ||
Volume (30-day avg) 1.4M shares | Beta 2.57 | 52 Weeks Range 6.24 - 21.24 | Updated Date 10/18/2026 |
52 Weeks Range 6.24 - 21.24 | Updated Date 10/18/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.22 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Therapeutic Development | Clinical trial progression, milestone payments from partners, and potential future drug sales. | The company earns money by advancing drug candidates toward regulatory approval and potential partnership or commercialization. |
Valuation
Trailing PE 13.28 | Forward PE 87.72 | Enterprise Value 1.53B | Price to Sales(TTM) 30.52 |
Enterprise Value 1.53B | Price to Sales(TTM) 30.52 | ||
Enterprise Value to Revenue 39.82 | Enterprise Value to EBITDA 163.68 | Shares Outstanding 72.39M | Shares Floating 69.29M |
Shares Outstanding 72.39M | Shares Floating 69.29M | ||
Percent Insiders 4.08 | Percent Institutions 51.36 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.